Agency updates emergency use authorization for the Moderna and Pfizer-BioNTech COVID-19 vaccinations, which are no longer authorized for used in the United States.

The risk is particularly high in the first 2 years after an HIV diagnosis.

This drug is the first to control complement factor C5a, which is a protein that plays a significant but potentially harmful role in the body's immune response.

Rezafungin (Rezzayo; Cidara Therapeutics Inc, Melinta Therapeutics LLC) is the first new treatment option approved for individuals with candidemia and invasive candidiasis in more than a decade.

Findings from the ongoing Adult Respiratory Syncytial Virus phase 3 trial suggest RSVPreF3 OA vaccine is effective and safe for individuals aged 60 years and older.

Persistently pursuing valued goals and adjusting those goals in response to setbacks or obstacles may help explain how some individuals with chronic pain maintain their mental wellbeing.

Findings from the AFFIRM trial found increased risks after stopping oral anticoagulant therapy after rhythm control, and the same is true for stopping treatment with oral anticoagulants after successful ablation.

Ideally, older patients receive vaccinations by October, but disease activity often peaks in February or March.

US adults have a slightly stronger preference for fewer adverse events in relation to pediatric COVID-19 vaccination, study results show.

Migraine could be considered a clinical marker of increased obstetric risk in pregnant women.

This is the largest known study to consider medical and recreational cannabis policies with US psychosis-related health care claims.

The supplemental new drug application is based on results from a landmark phase 3 trial showing that empagliflozin tablets provided meaningful results.

The vaccine was 88% effective at preventing pertussis among infants younger than 2 months when administered during the third trimester of pregnancy.

The number of Mpox cases is expected to rise, which requires ongoing testing, vaccinations, and medication services by health care providers.

Intravenous tocilizumab (Actemra; Genentech) has been approved for the treatment of COVID-19 in individuals who are hospitalized and receiving systemic corticosteroids and supplemental oxygen.

There are limited data on the efficacy of boosters for preventing infection and death in nursing home residents, but the findings suggest that boosters may have significantly reduced COVID-19–associated morbidity and mortality in this population.

Booster shots updated for the Omicron variant BA.4 and BA.5 lineages cleared for children 6 months through 4 years of age.

Parties and get-togethers often present challenges for patients with allergies, particularly with home-cooked food that may have unclear ingredients.

Although long-term health issues from COVID-19 are a major public health concern, evidence on post-COVID-19 symptoms are still limited, specifically among children and adolescents.

A feature of obesity and type 2 diabetes is vascular insulin, which contributes to vascular disease.

Pharmacists can remind parents to have an EpiPen on hand and to carefully review candy after trick-or-treating.

Investigators find that individuals aged 5 to 14 years with the genetic disorder are also at greater risk for TD2.

A Mediterranean-style diet appears to provide the greatest benefit to a healthy gut microbiome and brain.

Data from a recent study show a clear need to further reduce the number of hours residents work each week on average to decrease the occurrence of depression.

Data show that an increase in sexual assault-related emergency department visits in 2019 may be due to social de-stigmatization of sexual assault during the #metoo movement of that year.